In This Article:
The market has been flat in the last week, but it is up 8.0% over the past year, with earnings forecasted to grow by 14% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on companies with strong financials and solid fundamentals, these stocks can present valuable prospects for those willing to explore beyond traditional investment avenues.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Safe Bulkers (NYSE:SB) | $3.42 | $358.57M | ★★★★☆☆ |
IDenta (OTCPK:IDTA) | $0.698616 | $2.83M | ★★★★★★ |
Tuya (NYSE:TUYA) | $2.32 | $1.39B | ★★★★★★ |
WM Technology (NasdaqGS:MAPS) | $1.12 | $188.36M | ★★★★★★ |
Flexible Solutions International (NYSEAM:FSI) | $4.45 | $56.28M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.74 | $94.3M | ★★★★★★ |
BAB (OTCPK:BABB) | $0.83935 | $6.1M | ★★★★★★ |
Dingdong (Cayman) (NYSE:DDL) | $2.42 | $518.62M | ★★★★★★ |
Lifetime Brands (NasdaqGS:LCUT) | $3.23 | $72.4M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.8999 | $80.94M | ★★★★★☆ |
Click here to see the full list of 757 stocks from our US Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Corvus Pharmaceuticals
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates targeting proteins essential for immune cell maturation and function in the United States, with a market cap of $301.84 million.
Operations: Corvus Pharmaceuticals, Inc. does not report any revenue segments as it is focused on developing product candidates in the clinical stage.
Market Cap: $301.84M
Corvus Pharmaceuticals, with a market cap of US$301.84 million, is pre-revenue and currently focused on clinical-stage product development. The company recently reported a net income of US$15.19 million for Q1 2025, marking an improvement from the previous year's loss. Corvus's cash runway extends over a year, supported by its debt-free status and sufficient short-term assets covering liabilities. Despite high volatility in share price and ongoing unprofitability, recent positive interim data from its Phase 1 trial for soquelitinib in atopic dermatitis shows potential efficacy and safety benefits, offering promise amidst financial challenges.
-
Jump into the full analysis health report here for a deeper understanding of Corvus Pharmaceuticals.
-
Learn about Corvus Pharmaceuticals' future growth trajectory here.
Definitive Healthcare
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform both in the United States and internationally, with a market cap of approximately $539.99 million.